Neptune (000078)_ Introduction. Neptune Star Bio, formerly known as Shenzhen Shekou Neptune Star Bio-engineering Co., Ltd., was approved by Shenzhen Nanshan District People's Government on February 3, 20 10, and was established by Shennanfu (1992)18. 1On July 25th, 1996, Shenzhen Securities Regulatory Bureau approved the reorganization of public joint-stock company with Shenzhen Securities Office's reply (1996) No.68. On April 6th, 1997, Shenzhen Wanghai Bioengineering Co., Ltd. was approved by Shenzhen Administration for Industry and Commerce, with a share capital of 57.3 million yuan.
Significant progress has been made in independent innovation of Neptune's biological tumor drugs. Shenzhen Wanghai Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Wanghai Bio, applied for the patent of "Phenylnitrone Compounds Containing Stilbene Fragments and Their Uses" and was authorized by China National Intellectual Property Administration.
According to the patent abstract, the patent can be used to treat hyperproliferative diseases of mammalian cells, such as cancer, and can also be used as a neuroprotective agent. At the same time, the invention also discloses a pharmaceutical composition containing these compounds and its application in preparing anti-tumor drugs.
According to industry insiders, once a patent is granted, it is an exclusive drug, which can only be produced by a company with a patent and has market exclusivity. China has been encouraging pharmaceutical companies to innovate independently and promote industrial upgrading. Patented drugs are the symbol that can best reflect the independent intellectual property rights and R&D strength of enterprises.
The National Development and Reform Commission (NDRC) is planning to liberalize some drug prices. The first category is drugs authorized by national patents. During the "two sessions", medical representatives suggested that the state should support the provinces in policy to maintain the high bidding price of patented drugs and give some financial support at the same time.
2065438+On March 4th, 2004, the three major anti-tumor drugs, Jimmy Pamine, Autracil Potassium and S- 1 tablet, declared by Fuzhou Haiwangfu Pharmaceutical Co., Ltd. and Shenzhen Wanghai Pharmaceutical Co., Ltd., were sent to the State Pharmaceutical Products Supervision and Administration for production approval. This means that the company's anti-tumor product line has been further improved, and the future anti-tumor drug business is expected to become a new attraction.
Among them, jimpamine and potassium oteracil are one of the components of anti-cancer drug S- 1, which can inhibit the toxic and side effects of anti-tumor drug tegafur. What deserves more attention is S- 1 tablet for the treatment of gastric cancer. According to public information, more than 80% cases of advanced gastric cancer in Japan are treated with S- 1. Domestic S- 1 capsule has been released rapidly since it was listed in 2009, with a compound growth rate of 65,438+00-2065,438+024% in 2065,438+02. In 2065,438+02, the domestic sales volume was about 446 million yuan, and the estimated terminal scale was close to 65,438+04 million yuan, ranking among the top ten domestic antineoplastic drugs. In addition to Neptune Bio, Qilu Pharmaceutical, Hengrui Pharma, and Shandong * * Pharmaceutical also have approvals for this drug.
Anti-tumor drugs are the main products of Neptune biomedical industry, and the company has developed a variety of widely known anti-cancer products. On February 4th, last year, Nepstar Bio won the special science and technology appropriation of Shenzhen Nanshan Finance Bureau10.5 million yuan for the company's "research and development of new anti-tumor drugs and core technologies" project. 20 14 10 17, the company's small-capacity injection workshop (anti-tumor drugs) obtained GMP certification.